Global Hypogonadism Drug Market – Industry Trends and Forecast to 2031

Hypogonadism Drug Market Analysis and Size

The hypogonadism drug market is rapidly advancing with new technologies and methods, fostering significant growth. Innovations in testosterone replacement therapies and novel delivery systems are reshaping treatment options, enhancing efficacy, and improving patient adherence and outcomes. For instance, according to Boston University School of Medicine, around 4 to 5 million men in the U.S. suffer from hypogonadism. Low testosterone levels are particularly prevalent in older males, with over 60% of men over 65 having free testosterone levels below those of men aged 30 to 35, indicating a promising future for comprehensive hormonal deficiency treatment.                         

The global hypogonadism drug market size was valued at USD 9.50 billion in 2023, is projected to reach USD 12.99 billion by 2031, with a CAGR of 4.0% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Hypogonadism, a condition where the body doesn't produce enough testosterone, is often treated with hormone replacement therapy (HRT). Testosterone replacement drugs, such as testosterone cypionate or testosterone gel, are commonly used. These medications help restore testosterone levels to normal, alleviating symptoms such as low libido, fatigue, and reduced muscle mass. Treatment is tailored based on individual needs and monitored closely by healthcare providers.           

Hypogonadism Drug Market Dynamics

Drivers

• Increasing Prevalence of Postmenopausal Disorders

The increasing prevalence of postmenopausal disorders, such as osteoporosis and sexual dysfunction, contributes to a rising incidence of hypogonadism among elderly women. For instance, in 2021, over half of Thailand's population aged 65 and above were women, accounting for more than 9% of the total population. By 2050, this demographic is expected to double to over 18%. This demographic shift underscores a growing need for hypogonadism treatments to address declining testosterone levels, driving market expansion.

• Increasing Government Initiatives

Government initiatives and regulatory approvals significantly bolster market growth in hypogonadism treatment. For instance, in 2019, Clarus Therapeutics secured FDA approval for Jatenzo, an oral testosterone replacement therapy for primary and hypogonadotropic hypogonadism in men. Similarly, Antares Pharma's FDA approval of Xyosted in 2018 further exemplifies this trend. These approvals not only expand treatment options but also enhance patient access and confidence, driving increased adoption and market expansion in the hypogonadism drug sector.

Opportunities

• Expanded Indications

Testosterone therapy's potential extends beyond hypogonadism to include chronic diseases and sexual dysfunction, broadening its market impact. For instance, studies indicate its benefits in improving muscle strength and bone density in elderly men, reducing risks of fractures and frailty. Furthermore, its role in addressing sexual dysfunction, such as erectile dysfunction, enhances its appeal across demographics. Such expanded indications not only increase patient pool but also drive innovation in treatment approaches, fostering growth in the testosterone therapy market.

• Increasing Prevalence of Hypogonadism

The increasing prevalence of hypogonadism, exacerbated by global obesity trends and age-related hormonal declines, significantly drives market growth. According to a 2019 NIH report, obesity contributes to a higher incidence of hypogonadism in males. Men aged 60-80 typically experience testosterone levels 20-80% lower than younger men. This demographic, with the highest incidence of hypogonadism, underscores the substantial market opportunity for effective treatments addressing hormonal deficiencies in aging populations, thereby shaping pharmaceutical advancements and market expansion.

Restraints/Challenges

• Side Effects of Hypogonadism Drug

Side-effects of hypogonadism drugs include irregular heartbeat, breast swelling, vaginal dryness, and osteoporosis in women undergoing hormone replacement therapy. These adverse effects hinder market growth due to safety concerns and patient reluctance to undergo treatment, impacting adoption rates and overall market expansion. 

• Long-term Efficacy and Compliance

Long-term efficacy and patient compliance pose significant hurdles for the hypogonadism drug market. Challenges include maintaining treatment effectiveness over extended periods and ensuring patients adhere to complex therapy regimens. These factors contribute to uncertainties in treatment outcomes and can deter market growth due to unpredictable patient responses and management difficulties for healthcare providers. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hypogonadism Drug Market Scope

The market is segmented on the basis of therapy, drug delivery, type, route of administration, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

• Testosterone Replacement Therapy
• Estrogen Therapy
• Progesterone Therapy

 Drug Delivery

• Topical Gels
• Injectable
• Transdermal Patches
• Others

 Type

• Hypergonadotropic Hypogonadism
• Hypogonadotropic Hypogonadism

 Route of Administration

• Oral
• Injectable
• Transdermal Patch
• Implantable Pellet
• Tropical

 End-Users

• Hospitals,
• Homecare
• Specialty Clinics
• Others

Hypogonadism Drug Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, therapy, drug delivery, type, route of administration, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow in the hypogonadism drug market due to rising cases of the condition and increasing awareness about hormonal disorders. The expanding patient population in the region is anticipated to further drive market growth in the upcoming years.

North America is expected to dominates the hypogonadism drug market is anticipated due to increased adoption of advanced products. Enhanced healthcare infrastructure and availability of drugs for hypogonadism and rising awareness about hormonal disorders and treatment options will propel market growth in the region during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Hypogonadism Drug Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• AbbVie inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
•  Sun Pharmaceutical Industries Ltd. (India)
• Hikma Pharmaceuticals PLC (Japan)
• Amneal Pharmaceuticals LLC. (U.S.)
• Alvogen (U.S)
• Teva Pharmaceutical Industries Ltd (Israel)
• Endo Pharmaceuticals plc (Ireland)
• Perrigo Company plc (U.S.)
• Johnson & Johnson Services, Inc (U.S.)
• Ferring B.V. (Switzerland)
• Antares Pharma (U.S.)
• Aytu BioPharma, Inc. (U.S.)
• HYUNDAIPHARM. Co., Ltd (South Korea)

SKU-42541